Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 7/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.45 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | PAK4 | O96013 | 1/20 | 0.39 |
| ▸ | PRKCB | P05771 | 3/20 | 0.38 |
| ▸ | NPC1 | O15118 | 3/20 | 0.38 |
| ▸ | RAB9A | P51151 | 2/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | FABP1 | P07148 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5451964 | 0.91 | POLB (0.41) | DGAT1CYP3A4SOAT1POLBNPSR1 | |
| SCHEMBL5451912 | 0.89 | ACHE (0.41) | DGAT1CYP3A4SOAT1PAK4PRKCB | |
| SCHEMBL5448161 | 0.88 | NPC1 (0.49) | DGAT1CYP3A4SOAT1NPC1RAB9A | |
| SCHEMBL5451386 | 0.88 | FLT3 (0.43) | PAK4PRKCBNPC1RAB9ASMN1; SMN2 | |
| SCHEMBL5449475 | 0.88 | DGAT1 (0.46) | DGAT1CYP3A4SOAT1POLBNPSR1 | |
| SCHEMBL6236756 | 0.87 | POLB (0.37) | DGAT1CYP3A4SOAT1POLBNPSR1 | |
| SCHEMBL5451831 | 0.83 | CDK2 (0.42) | POLBNPSR1SCN9ASMN1; SMN2HTT | |
| SCHEMBL5449453 | 0.83 | NPC1 (0.43) | DGAT1CYP3A4SOAT1PRKCBNPC1 | |
| SCHEMBL5448086 | 0.82 | NPC1 (0.43) | DGAT1CYP3A4SOAT1POLBNPC1 | |
| SCHEMBL5454768 | 0.81 | FLT3 (0.41) | DGAT1CYP3A4SOAT1PAK4PRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | claimed |
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | PFIZER ITALIA S.R.L. (IT) | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037790-A1 | Bicyclo-pyrazole derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them | MAP3K15, MAP3K7, MAP3K19 | DGAT1 4416/4885CYP3A4 2904/4885SOAT1 4171/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.